Stay updated on RMC-6236 in RAS Mutant Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page.

Latest updates to the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page
- Check3 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2; the page content remains a 403 Forbidden error.SummaryDifference0.2%

- Check10 days agoChange DetectedThe footer shows site revision v3.7.1 instead of v3.7.0. The page continues to display a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe page now displays a 403 error, replacing the usual study details and navigation with an error display. This indicates that access to the study record is blocked.SummaryDifference19%

- Check45 days agoChange DetectedA new Publications entry has been added, listing authors and a NEJM 2026 article on Daraxonrasib for previously treated RAS-mutant cancers. This update connects the study to recent related research and provides readers with a current reference.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6, indicating a new version of the study record on the ClinicalTrials.gov page. The update reflects page-level versioning rather than changes to the study data presented.SummaryDifference0.0%

- Check73 days agoChange DetectedThe revision tag on the page updated from v3.6.4 to v3.6.5. This indicates a minor update to the page content or underlying software.SummaryDifference0.0%

Stay in the know with updates to RMC-6236 in RAS Mutant Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page.